Endonovo Therapeutics, Inc. (ENDV) to Acquire Rio Grande Neurosciences

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Endonovo Therapeutics, Inc. (OTC: ENDV) announced it has executed a binding letter of intent (LOI) to acquire Rio Grande Neurosciences, Inc. (RGN), a privately-held clinical stage developer of non-invasive Electroceuticals™ for the treatment of neuro-inflammation and central nervous system diseases and disorders. The LOI is binding, but subject to the execution of a definitive purchase agreement, shareholder approvals from both companies and Endonovo raising additional capital. The parties expect to sign a definitive agreement within the third quarter ending September 30, 2016 and close at the same time or shortly thereafter. Endonovo has paid $500,000 towards the purchase price through the issuance of a note. Pursuant to the LOI, Endonovo will be…

Link to Full Article: Endonovo Therapeutics, Inc. (ENDV) to Acquire Rio Grande Neurosciences

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!